Encysive Pharmaceuticals (ENCY) Inactive 10-Q2005 Q1 Quarterly report

Filed: 29 Apr 05, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: administer, AG, alternative, annum, assigned, begin, beginning, begun, broader, cancel, Chief, competing, competitive, component, concluded, consecutive, conversion, deemed, delayed, developmental, distribution, dollar, economic, educational, enforcing, entirety, establish, establishing, Europe, eventual, expand, experience, expressly, field, foreseeable, formulating, fundamental, governmental, hedged, hiring, implementation, inability, indenture, infrastructure, intellectual, issuable, iv, judgment, licensee, lieu, mailed, maintain, negative, nominal, notice, ownership, patent, permitted, personnel, plaque, Plough, portion, position, positive, predict, priority, professional, profit, promotional, promulgated, property, prosecuting, prospective, psoriatic, rank, redeem, redemption, reimbursement, released, repurchase, restructure, restructuring, retained, scale, Schering, service, showed, similarly, specifically, subordinated, supply, surviving, terminology, Thelin™and, therapeutic, thereof, unamortized, uncertainty, underwriter, underwriting, Union, variability, waived, warehousing

Removed: accounted, acquired, actively, Add, Administration, afflict, agency, arm, Assessment, autoimmune, binding, blood, bosentan, breath, characterized, check, children, classified, closing, collateral, conclusion, conducted, confirming, congenital, constriction, daily, death, Deduct, deterioration, distance, dividend, duration, Employer, endpoint, exclusive, expired, extreme, fashion, filed, filer, Food, functional, Genentech, genetic, Hatch, Health, heart, HIV, human, Identification, important, infection, initiate, initiated, Intangible, issuer, January, joint, jurisdiction, leading, life, limitation, liver, living, mark, noncash, operate, order, PAGE, paid, par, partner, past, perform, practicable, preceding, Preferred, preparing, pressure, prevalence, prime, projecting, Protocol, pump, Qualitative, Quantitative, randomized, reached, repay, reset, responsible, schedule, scleroderma, secondary, shared, shorter, SPA, sponsor, step, suffer, Supplemental, supportive, TRANSITION, unrealized, ventricular, volatility, Vote, walk, warrant, WASHINGTON, Waxman, women, yield, young

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ENCY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Encysive Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2005 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Stephen L. Mueller, Vice President, Finance and Administration, Secretary and Treasurer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Stephen L. Mueller
Stephen L. Mueller
Vice President, Finance and Administration
Secretary & Treasurer

April 29, 2005

A signed original of this written statement required by Section 906 has been provided to Encysive Pharmaceuticals Inc. and will be retained by Encysive Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.